WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Konstantinos Andrikopoulos, Ph.D., J.D., has joined the company as Vice President, Legal Counsel and Chief Intellectual Property Counsel.
